Positive News on Roche's Perjeta Roche recently received positive news when the FDA's Oncologic Drugs Advisory Committee voted in favor of recommending accelerated approval of Perjeta regimen for neoadjuvant treatment in HER2+ early stage ...
Sept. 13, 2013 - Zacks via Yahoo! Finance
FDA Advisory Committee Recommends Accelerated Approval of Genentech’s Perjeta for Neoadjuvant Use in HER2-Positive ... Genentech, a member of the Roche Group , today announced that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee voted 13 to 0, with one abstention, in favor of recommending accelerated approval of a Perjeta® regimen for neoadjuvant treatment in people with high-risk, HER2-positive early stage breast cancer.
Sept. 12, 2013 - Business Wire via Yahoo! Finance